193 related articles for article (PubMed ID: 31111393)
1. Androgen deprivation therapy and the risk of tenosynovitis in prostate cancer patients.
Liu JM; Liu DW; Chuang HC; Wu CT; Lin CY; Hsu RJ
Int Urol Nephrol; 2019 Jul; 51(7):1113-1119. PubMed ID: 31111393
[TBL] [Abstract][Full Text] [Related]
2. Different androgen deprivation therapies might have a differential impact on cognition - An analysis from a population-based study using time-dependent exposure model.
Hong JH; Huang CY; Chang CH; Muo CH; Jaw FS; Lu YC; Chung CJ
Cancer Epidemiol; 2020 Feb; 64():101657. PubMed ID: 31918180
[TBL] [Abstract][Full Text] [Related]
3. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
[TBL] [Abstract][Full Text] [Related]
4. Statin reduces the risk of dementia in diabetic patients receiving androgen deprivation therapy for prostate cancer.
Liu JM; Chen TH; Chuang HC; Wu CT; Hsu RJ
Prostate Cancer Prostatic Dis; 2019 May; 22(2):276-283. PubMed ID: 30337635
[TBL] [Abstract][Full Text] [Related]
5. Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study.
Wu YH; Jhan JH; Ke HL; Tseng SI; Chang YH; Yeh HC; Li CC; Lee YC
Int J Clin Pharm; 2020 Dec; 42(6):1433-1439. PubMed ID: 32951178
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.
Wu CT; Yang YH; Chen PC; Chen MF; Chen WC
Osteoporos Int; 2015 Sep; 26(9):2281-90. PubMed ID: 25990353
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation therapy did not increase the risk of Alzheimer's and Parkinson's disease in patients with prostate cancer.
Chung SD; Lin HC; Tsai MC; Kao LT; Huang CY; Chen KC
Andrology; 2016 May; 4(3):481-5. PubMed ID: 27062333
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases.
Liu JM; Yu CP; Chuang HC; Wu CT; Hsu RJ
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):475-482. PubMed ID: 30692587
[TBL] [Abstract][Full Text] [Related]
9. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Rheumatoid Arthritis: A Population-Based Cohort Study.
Klil-Drori AJ; Santella C; Tascilar K; Yin H; Aprikian A; Azoulay L
Drug Saf; 2019 Aug; 42(8):1005-1011. PubMed ID: 31240687
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
11. Decreased Risk of Renal Calculi in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer.
Lin CY; Liu JM; Wu CT; Hsu RJ; Hsu WL
Int J Environ Res Public Health; 2020 Mar; 17(5):. PubMed ID: 32182733
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer.
Lin CC; Gray PJ; Jemal A; Efstathiou JA
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25957435
[TBL] [Abstract][Full Text] [Related]
13. No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: a 5-year follow-up study.
Kao LT; Lin HC; Chung SD; Huang CY
Asian J Androl; 2017; 19(4):414-417. PubMed ID: 27232853
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation therapy for prostate cancer and the risk of thyroid diseases.
Liu JM; Chen YT; Wu CT; Hsu WL; Hsu RJ
Prostate; 2022 May; 82(7):809-815. PubMed ID: 35226371
[TBL] [Abstract][Full Text] [Related]
15. Androgen Deprivation Therapy Use Increases the Risk of Heart Failure in Patients With Prostate Cancer: A Population-Based Cohort Study.
Kao HH; Kao LT; Li IH; Pan KT; Shih JH; Chou YC; Wu ST
J Clin Pharmacol; 2019 Mar; 59(3):335-343. PubMed ID: 30402905
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders.
Liu JM; Liu YP; Chuang HC; Wu CT; Su YL; Hsu RJ
PLoS One; 2020; 15(2):e0229263. PubMed ID: 32074125
[TBL] [Abstract][Full Text] [Related]
17. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F
Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492
[TBL] [Abstract][Full Text] [Related]
18. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.
Klil-Drori AJ; Yin H; Tagalakis V; Aprikian A; Azoulay L
Eur Urol; 2016 Jul; 70(1):56-61. PubMed ID: 26138040
[TBL] [Abstract][Full Text] [Related]
19. Correlation of Androgen Deprivation Therapy with Cognitive Dysfunction in Patients with Prostate Cancer: A Nationwide Population-Based Study Using the National Health Insurance Service Database.
Tae BS; Jeon BJ; Shin SH; Choi H; Bae JH; Park JY
Cancer Res Treat; 2019 Apr; 51(2):593-602. PubMed ID: 30025445
[TBL] [Abstract][Full Text] [Related]
20. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
